Efe Orhan, Sauvage Gabriel, Jeyabalan Anushya, Al Jurdi Ayman, Seethapathy Harish S, Cosgrove Katherine, Cortazar Frank B, Laliberte Karen A, Zonozi Reza, Niles John L
Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kidney Int Rep. 2025 Feb 7;10(5):1441-1449. doi: 10.1016/j.ekir.2025.02.002. eCollection 2025 May.
Persistent B cell depletion is a rare complication of rituximab treatment, and its clinical implications are unknown.
This retrospective case series included patients with glomerular and autoimmune diseases who developed persistent B cell depletion (< 5 CD19CD20 cells/μl persisting for > 2 years) after the last rituximab dose.
Among 1519 patients who received rituximab, 2% ( = 30) had persistent B cell depletion. The frequencies of persistent B cell depletion were 2.5% (22 of 878), 2.4% (2 of 82), and 0.8% (1 of 114) in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus (SLE) or lupus nephritis, and podocytopathies, respectively. The remaining patients had ANCA-negative vasculitis ( = 2), anti-glomerular basement membrane disease ( = 1), Behcet's disease ( = 1), and polymyositis ( = 1). The median age was 64.5 (interquartile range [IQR]: 44-77) years. Before the last dose of rituximab, all patients except 2 used cytotoxic agents, often prolonged (> 1 year) or recycling courses, and 60% (18 of 30) received a period of long-term maintenance steroids. By 4 years after the last rituximab dose, only 30% had B cell repopulation. In those who experienced B cell repopulation, B cell counts remained very low, at a median of 7(6-15) cells/μl at the last follow-up. After the last rituximab dose, 83% (23 of 30) had sustained disease remission. Late-onset neutropenia, recurrent infections, and severe infections occurred in 23% (7 of 30), 47% (14 of 30), and 57% (17 of 57), respectively. Of the patients, 23% (7 of 30) required immunoglobulin replacement, and 30% (9 of 30) died, mostly from complications of chronic diseases.
Persistent B cell depletion is a rare complication of rituximab treatment, mostly affecting patients with exposure(s) to cytotoxic therapies for recurrent diseases. It is characterized by prolonged disease remission and increased infection risk.
持续性B细胞耗竭是利妥昔单抗治疗罕见的并发症,其临床意义尚不清楚。
本回顾性病例系列纳入了肾小球疾病和自身免疫性疾病患者,这些患者在最后一剂利妥昔单抗后出现持续性B细胞耗竭(<5个CD19⁺CD20⁺细胞/μl,持续超过2年)。
在1519例接受利妥昔单抗治疗的患者中,2%(n = 30)出现持续性B细胞耗竭。抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)、系统性红斑狼疮(SLE)或狼疮性肾炎以及足细胞病患者中持续性B细胞耗竭的发生率分别为2.5%(878例中的22例)、2.4%(82例中的2例)和0.8%(114例中的1例)。其余患者患有ANCA阴性血管炎(n = 2)、抗肾小球基底膜病(n = 1)、白塞病(n = 1)和多发性肌炎(n = 1)。中位年龄为64.5岁(四分位间距[IQR]:44 - 77岁)。在最后一剂利妥昔单抗之前,除2例患者外,所有患者均使用了细胞毒性药物,通常疗程延长(>1年)或循环使用,60%(30例中的18例)接受了一段长期维持性类固醇治疗。在最后一剂利妥昔单抗后4年时,只有30%的患者B细胞重新增殖。在那些经历B细胞重新增殖的患者中,B细胞计数仍然非常低,最后一次随访时中位计数为7(6 - 15)个细胞/μl。在最后一剂利妥昔单抗后,83%(30例中的23例)疾病持续缓解。迟发性中性粒细胞减少、反复感染和严重感染的发生率分别为23%(30例中的7例)、47%(30例中的14例)和57%(57例中的17例)。23%(7例中的30例)的患者需要免疫球蛋白替代治疗,30%(9例中的30例)死亡,多数死于慢性疾病并发症。
持续性B细胞耗竭是利妥昔单抗治疗罕见的并发症,主要影响因复发性疾病而接受细胞毒性治疗的患者。其特点是疾病缓解期延长和感染风险增加。